MediGene Announces Webcast of Analyst Conference and Conference Call of 2004 Year End Results Analyst Conference to be Held on March 23 in Frankfurt at 7:30 AM ET (1:30 PM CET) MARTINSRIED, Germany, and SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt: MDG) today announced that it will hold an Analyst Conference, in Frankfurt, on March 23, 2005 starting at 7:30 a.m. ET (1:30 p.m. CET) to discuss year-end results, status of its clinical development programs and 2005 guidance. The Analyst Conference will be hosted by Peter Heinrich, CEO; Alexander Dexne, CFO; Dr. Ulrich Delvos, Member of the Board for R&D, Dr. Axel Mescheder, Vice President Clinical Development; Dr. Uwe Michaelis, Vice President Research as well as the Coordinating Investigators Prof. Dr. Eggert Stockfleth, Clinic for Dermatology of the Charite, Berlin, and Prof. Dr. Matthias Lohr, Deputy Principal, Medical Clinic at University Hospital Mannheim. The live webcast of this event will be available through the MediGene website: http://www.medigene.com/. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the Company's web site. In addition MediGene announced today that its financial results for the year ended December 31, 2004 will be released prior to the opening of the U.S. financial markets on Wednesday, March 23, 2005. MediGene will hold an investor conference call to discuss year-end results and 2005 guidance on Thursday, March 24 at 9:00 a.m. ET (3:00 p.m. CET). To participate, the following toll free numbers are available: Germany: 0-800-181-3857 United States: 800-573-4842 To dial in outside of these countries you may dial either +49-69-22222-0560 or +1-617-224-4327 A replay of the call will be available until Thursday, March 31, 2005 at +1-888-286-8010 / +1-617-801-6888; access code 54309374. About MediGene: MediGene AG is a publicly quoted (Frankfurt: Prime Standard), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market: Eligard(R) against prostate cancer. A second drug is about to enter into approval process (clinical phase III completed). In addition, MediGene has several drug candidates in clinical development and possesses innovative platform technologies. MediGene's core competence lies in research and development of novel approaches for the treatment of various tumor diseases.. DATASOURCE: MediGene AG CONTACT: Julia Hofmann, Public Relations, +49-89-85-65-3324, or Dr. Michael Nettersheim, Investor Relations, +49-89-85-65-2946, both of MediGene AG, , Fax: +49-89-85-65-2920 Web site: http://www.medigene.com/

Copyright